Acute Myelogenous Leukemia - Adult (Greater than or equal to 18 years old)

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

Notes: Consider clinical trials as treatment options for eligible patients. Stem Cell Transplant guidelines are not included with this algorithm.

Note: Leukemia Patients should be referred and treated at a Comprehensive Cancer Center.

**INITIAL EVALUATION**

**TREATMENT**

**AML Subtypes**

- Acute Promyelocytic Leukemia
  - t(8:21) and inv(16)
  - **Complete remission?**
    - Yes → Maintenance\(^1\) or Surveillance
    - No → Clinical Trials\(^1\)

- Young less than 60-65 years
  - Idarubicin plus Cytarabine or Clinical Trials\(^1\)

- Older or not eligible for Intensive chemotherapy
  - Low intensity therapy\(^1\) or Clinical Trials\(^1\)

- Other
  - Arsenic Trioxide plus All-Trans Retinoic Acid (ATRA) with or without idarubicin OR
  - Consider clinical trial: Arsenic Trioxide plus All-Trans Retinoic Acid (ATRA) with or without gemtuzumab ozogamicin\(^1\)

1Leukemia Newsletter www address: http://www.mdanderson.org/leukemia (Available programs-treatment priorities)
Acute Myelogenous Leukemia - Adult (Greater than or equal to 18 years old)

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson’s specific patient population; MD Anderson’s services and structure; and MD Anderson’s clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

Notes: Consider clinical trials as treatment options for eligible patients. Stem Cell Transplant guidelines are not included with this algorithm. Note: Leukemia Patients should be referred and treated at a Comprehensive Cancer Center

SUGGESTED READINGS

This practice guideline is based on majority expert opinion of the Leukemia Center Faculty at the University of Texas MD Anderson Cancer Center.

It was developed using a multidisciplinary approach that included input from the following medical oncologists:

- Yesid Alvarado, MD
- Michael Andreeff, MD
- Kapil Bhalla, MD
- Christopher Benton, MD
- Gautam Borthakur, MD
- Prithviraj Bose, MD
- Jan Burger, MD
- Jorge Cortes, MD
- Naval Daver, MD
- Courtney DiNardo, MD
- Zeev Estrov, MD
- Alessandra Ferrajoli, MD
- Emil Freireich, MD
- Guillermo Garcia-Manero, MD
- Elias Jabbour, MD
- Kiran Naqvi, MD
- Jain Nitin, MBBS
- Hagop M. Kantarjian, MD
- Tapan Kadia, MD
- Michael Keating, MD
- Marina Konopleva, MD
- Steven Kornblau, MD
- Maro Ohanian, DO
- Naveen Pemmaraju, MD
- Farhad Ravandi-Kashani, MD
- Mary Beth Rios, RN
- Michael Rytting, MD
- Koichi Takahashi, MD
- Philip Thompson, MBBS
- Srdan Verstovsek, MD
- William Wierda, MD

Core Development Team

Notes: Consider clinical trials as treatment options for eligible patients.

Note: Leukemia Patients should be referred and treated at a Comprehensive Cancer Center.

DEVELOPMENT CREDITS

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

Stem Cell Transplant guidelines are not included with this algorithm.

Acute Myelogenous Leukemia - Adult (Greater than or equal to 18 years old)